Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.

ABSTRACT:

Background

Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) by May 31, 2021. After early reports of myocarditis during adverse events monitoring, the Israeli Ministry of Health initiated active surveillance.

Methods

We retrospectively reviewed data obtained from December 20, 2020, to May 31, 2021, regarding all cases of myocarditis and categorized the information using the Brighton Collaboration definition. We analyzed the occurrence of myocarditis by computing the risk difference for the comparison of the incidence after the first and second vaccine doses (21 days apart); by calculating the standardized incidence ratio of the observed-to-e

SUBMITTER: Mevorach D 

PROVIDER: S-EPMC8531987 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature